

IFW

PATENT APPLICATION

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of

Docket No: Q89135

Kunio YASUNAGA, et al.

Appln. No.: 10/551,964

Group Art Unit: 1644

Confirmation No.: 3948

Examiner: NOT YET ASSIGNED

Filed: October 15, 2005

For: METHOD OF SCREENING ANTI-OBESITY AGENTS AND ANIMAL MODEL OF OBESITY

INFORMATION DISCLOSURE STATEMENT
UNDER 37 C.F.R. §§ 1.97 and 1.98

MAIL STOP AMENDMENT

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

Sir:

In accordance with the duty of disclosure under 37 C.F.R. § 1.56, Applicant hereby notifies the U.S. Patent and Trademark Office of the documents which are listed on the attached PTO/SB/08 A & B (modified) form and/or listed herein and which the Examiner may deem material to patentability of the claims of the above-identified application.

Copies of the listed documents are submitted herewith, along with a copy of an English translation of the corresponding International Search Report (ISR) from the Japanese Patent Office (counterpart Application No. PCT/JP2004/007692), except for the following: U.S. patents and/or U.S. patent publications; and co-pending non-provisional U.S. applications filed after June 30, 2003.


The present Information Disclosure Statement is being filed before the mailing date of the first Office Action on the merits, and therefore no Statement under 37 C.F.R. § 1.97(e) or fee under 37 C.F.R. § 1.17(p) is required.

In compliance with the concise explanation requirement under 37 C.F.R. § 1.98(a)(3) for foreign language documents, Applicants note that the attached document (JP 2000-300263) was cited in the enclosed International Search Report; a copy of an English language Abstract is also attached.

The submission of the listed documents is not intended as an admission that any such document constitutes prior art against the claims of the present application. Applicant does not waive any right to take any action that would be appropriate to antedate or otherwise remove any listed document as a competent reference against the claims of the present application.

The USPTO is directed and authorized to charge all required fees, except for the Issue Fee and the Publication Fee, to Deposit Account No. 19-4880. Please also credit any overpayments to said Deposit Account.

Respectfully submitted,



Joseph J. Ruch, Jr.
Registration No. 26,577

SUGHRUE MION, PLLC
Telephone: (202) 293-7060
Facsimile: (202) 293-7860

WASHINGTON OFFICE

23373

CUSTOMER NUMBER

Date: March 8, 2006

Substitute for Form 1449 A & B/PTO		Complete if Known	
		Application Number	10/551,964
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>		Confirmation Number	3948
		Filing Date	October 15, 2005
		First Named Inventor	Kunio YASUNAGA
		Art Unit	1644
		Examiner Name	NOT YET ASSIGNED
Sheet 1 of 1		Attorney Docket Number	Q89135

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Document Number		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document
		Number	Kind Code ² (if known)		
		US 2003/0105013	A1	06-06-2003	Baker et al.
		US			
		US			
		US			
		US			
		US			
		US			
		US			
		US			

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document			Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Translation ⁶
		Country Code ³	Number ⁴	Kind Code ⁵ (if known)			
		JP	2000-300263	A	10-31-2000	Helix Research Institute	English Abstract and cited in ISR
		WO	99/15653	A1	04-01-1999	Genentech, Inc.	
		EP	1 489 179	A1	03-27-2003	Yamanouchi Pharmaceutical Co. Ltd.	

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city, and/or country where published.	Translation ⁶
		OIKE, Y et al, Antiopietin-related growth factor (AGF) promotes epidermal proliferation, remodeling, and regeneration, Proc. Natl. Acad. Sci., USA, 2003, vol. 100, pages 9494 to 9499	
		OIKE, Y. et al, Mast Cell-Released Novel Angiopoietin-Related Growth Factor (AGF) Promotes Angiogenesis and Epidermal Proliferation, No. 1393, Circulation, 2002, 106, 19, p. II-276-277	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² See Kind Codes of USPTO Patent Documents at www.uspto.gov, MPEP 901.04 or in the comment box of this document. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST. 3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to indicate here if English language Translation is attached.